Ann: Recruitment of patients completed for Part B of TACTI-002, page-5

I was wondering the same thing. The lung cancer results were as equally impressive as the head and neck, imo.

Regardless, recruitment is flying ahead. There’s going to be some real anticipation around anything to do with Tacti002 and now 003 moving forward.

Look at IMU the stock is going off the chart for what reason I have no idea. They’ve just had results around Her-Vaxx,that used to be its poster child, that were not statistically significant. And with the small numbers of patients they are back to the drawing board with more ph2 trials before they get anywhere.
Meanwhile, we are getting fast tracked by the FDA pulling 15% complete responses and moving into phase3. And look at the share price difference! Makes no sense to me.